ArticlePulmonary medicine2026
Outcomes and Prognostic Analysis of Therapeutic Bronchoscopy in Non-Small Cell Lung Cancer (NSCLC) Patients With Respiratory Failure Secondary to Malignant Central Airway Obstruction (MCAO).
Article in Pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of this study was to investigate the value of therapeutic bronchoscopy in malignant central airway obstruction (MCAO) patients secondary to non-small cell lung cancer (NSCLC), especially in those experiencing respiratory failure (RF).
methodsThis retrospective cohort study was conducted on 101 cases of NSCLC-related MCAO patients who received therapeutic bronchoscopy from January 2018 to January 2025. Patients were classified into the RF group (n = 39) and the non-RF group (n = 62) based on the presence of RF (PaO
resultsTherapeutic bronchoscopy achieved technical success in 93.1% of 101 patients, with no significant differences in technical success (p = 0.521), complication rates (p = 0.147), and short-term or intermediate-term efficacy between RF and non-RF groups. Kaplan-Meier curves indicated a median survival of 16.98 months posttherapeutic bronchoscopy, with univariate analysis revealing statistically significant differences between the RF and non-RF groups (10.46 months vs. 18.62 months, log - rank χ
conclusionTherapeutic bronchoscopy is safe and effective in NSCLC patients with MCAO. This intervention should be performed promptly when airway narrowing causes RF. The ECOG PS, serum LDH level, and systemic antitumor treatment might be independent factors affecting the prognosis of MCAO patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.